How Epigenetic Reprogramming Drives Cancer-Promoting Metalloproteinases
A detailed review reveals how DNA methylation and histone modifications control matrix metalloproteinases that drive cancer metastasis, pointing to new therapeutic targets.
Summary
Matrix metalloproteinases (MMPs) are enzymes that remodel the extracellular matrix and play critical roles in cancer spread, aging-related vascular stiffness, and inflammation. This comprehensive review from Dana-Farber Cancer Institute examines how epigenetic mechanisms — including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs — regulate MMP gene expression. Aberrant epigenetic activity in cancer cells can selectively upregulate MMPs, enabling tumor invasion and metastasis. Because direct MMP inhibitors have failed clinically due to toxicity and off-target effects, the authors argue that targeting upstream epigenetic regulators like EZH2, HDAC7, and TET2 offers a more precise and cancer-specific alternative. This approach could also address age-related vascular stiffness and inflammatory disease, expanding relevance beyond oncology.
Detailed Summary
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that remodel the extracellular matrix (ECM) and regulate a broad array of biological processes, from embryonic development and wound healing to vascular integrity and immune function. Their catalytic activity is normally constrained by tissue inhibitors of metalloproteinases (TIMPs) and by zymogen activation mechanisms requiring pro-peptide cleavage by enzymes such as furin or other MMPs. This review by Seehawer and Polyak of Dana-Farber Cancer Institute systematically maps how epigenetic machinery controls MMP expression and how its dysregulation enables cancer metastasis.
The review documents multiple layers of epigenetic control over MMP genes. DNA methylation at CpG islands near MMP promoters suppresses transcription, and loss of this methylation — for example, through reduced TET2 activity — can de-repress MMP9 in trophoblasts and cancer cells. Conversely, methylation of the RUNX2 promoter in osteoarthritis patients correlates inversely with MMP13 levels, illustrating indirect transcriptional control. Histone modifications add another layer: HDAC7 suppresses MMP10 in vascular endothelium during embryogenesis, while EZH2 upregulation after UV exposure increases MMP1 expression in fibroblasts by co-binding the MMP1 promoter with NF-κB subunits p50 and p65. Strikingly, declining EZH2 and H3K27me3 with age drives vascular stiffness by increasing MMP2-mediated elastin degradation, directly linking epigenetic aging to cardiovascular disease risk.
Chromatin remodeling complexes further modulate MMP expression. SMARCA4, a catalytic subunit of the SWI/SNF complex, binds the MMP2 promoter to increase expression in melanoma cells, while SMARCE1 positively regulates multiple MMPs in breast cancer cells. In contrast, loss of SMARCB1 homolog Snr in Drosophila elevates Mmp1 expression, illustrating the bidirectional capacity of remodelers. The INO80 complex similarly shows context-dependent effects: its knockdown in trophoblasts reduces MMP2 but raises TIMP1 and TIMP2 expression, resulting in embryonic lethality in knockout mice. Non-coding RNA regulation is also implicated, with lncRNA TETILA recruiting TET2 to the MMP9 promoter and miR-939 simultaneously upregulating MMP1, MMP3, and MMP9 in Staphylococcus aureus skin infection models.
In the metastatic cascade, MMPs contribute at virtually every step. Whole exome sequencing of 503 primary lung adenocarcinomas versus 73 brain metastases revealed significant MMP13 amplification in brain metastases. In breast cancer, MMP9 and MMP1 upregulation correlates with poor prognosis. MMP1 and MMP2, working with EREG and COX-2, are required for both tumor cell extravasation into lung tissue and angiogenesis in mammary tumor mouse models. Elevated MMP14 in breast cancer patients correlates with blood vessel invasion and high distant metastasis rates. The tumor microenvironment also contributes: neutrophil-derived MMP9 reawakens dormant cancer cells by remodeling laminin, and CD11b+ cells in pre-metastatic niches release MMP2 to degrade collagen and facilitate invasion of bone marrow-derived cells.
Because broad-spectrum MMP inhibitor trials have failed due to musculoskeletal toxicity and non-selectivity, the review proposes targeting epigenetic regulators that drive cancer-specific MMP expression. Epigenetically driven MMP upregulation is often confined to malignant cells, making upstream epigenetic targets such as EZH2 inhibitors, HDAC inhibitors, and DNMT inhibitors potentially more selective. However, the review cautions that many of these epigenetic regulators also control critical physiological MMP functions — for example, EZH2 inhibition could paradoxically worsen vascular stiffness by increasing MMP2 — underscoring the need for careful context-specific evaluation before clinical translation.
Key Findings
- Whole exome sequencing of 503 primary lung adenocarcinomas vs. 73 brain metastases showed significant MMP13 amplification specifically in brain metastases, indicating metastasis-driven genomic selection.
- EZH2 and H3K27me3 levels decline with age in vascular smooth muscle, increasing MMP2 expression and promoting elastin degradation; EZH2 inhibitor treatment in mice reproduced this vascular stiffening phenotype.
- SETDB2-induced H3K9me3 at TIMP1, TIMP2, and TIMP3 loci in monocytes suppresses all three inhibitors simultaneously, linking interferon-driven epigenetic changes to abdominal aortic aneurysm development.
- Neutrophil-derived MMP9 reawakens dormant cancer cells by laminin remodeling in mouse models; pharmacological inhibition of neutrophil MMP9 prevented this reawakening, suggesting a targetable dormancy-to-relapse transition.
- SMARCA4 binds the MMP2 promoter to upregulate expression in melanoma cells, while SMARCE1 positively regulates multiple MMP genes in breast cancer cells, implicating SWI/SNF subunits as context-specific MMP drivers.
- miR-939 induction during Staphylococcus aureus infection simultaneously upregulated MMP1, MMP3, and MMP9, facilitating pathogenic skin colonization in mouse models and illustrating RNA-mediated co-regulation of MMP clusters.
- MMP14 elevation in breast cancer patients correlated with blood vessel invasion and high rates of distant metastasis, and cancer cell-derived MMP14 induced further MMP14 expression in vascular endothelial cells via a paracrine feed-forward loop.
Methodology
This is a narrative review article compiling findings from primary experimental studies, mouse knockout models, clinical genomics datasets (including whole exome sequencing of 503 LUADs and 73 brain metastases), and in vitro cell culture experiments. No original experimental data or statistical analyses were conducted by the authors; conclusions are drawn from synthesizing published literature across oncology, vascular biology, immunology, and developmental biology. The breadth of evidence spans human patient cohorts, murine genetic models, and cell line studies, but no systematic meta-analytic methodology was applied.
Study Limitations
As a review article, this work is subject to selection bias in literature inclusion and does not present new experimental data, limiting causal conclusions. The authors acknowledge that many epigenetic regulators of MMPs (e.g., EZH2) serve dual physiological roles — inhibiting them in cancer contexts could paradoxically worsen age-related conditions such as vascular stiffness, representing a significant translational caveat. Conflict-of-interest disclosures were not available in the source excerpt reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: